文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

硫嘌呤治疗药物监测:降低6-硫鸟嘌呤核苷酸目标水平对炎症性肠病患者的影响

Therapeutic drug monitoring of thiopurines: Effect of reduced 6-thioguanine nucleotide target levels in inflammatory bowel disease patients.
PubMed 文献 · Br J Clin Pharmacol · 2022-03-29

该回顾性研究纳入151例接受硫唑嘌呤或巯嘌呤治疗的炎症性肠病患者,比较旧目标范围(600-1200 pmol/8×10^8 RBC)与调整后目标范围(320-630 pmol/8×10^8 RBC)下毒性停药发生率及疗效。

要点

  • 降低6-TGN目标范围后毒性停药有减少趋势但未达统计学显著。
  • 调整目标范围后未观察到疗效丧失的迹象。
  • 总人群52周时66%停药,其中毒性停药占48%。

核心结论

  • 降低6-TGN目标范围后毒性诱导的停药有减少趋势,但无统计学显著性。
  • 研究未发现降低目标范围会削弱疗效的任何迹象。

研究设计与样本

  • 回顾性研究,纳入接受硫唑嘌呤或巯嘌呤治疗的炎症性肠病患者共151例。
  • former target(FT)组76例,目标浓度600-1200 pmol/8×10^8 RBC;adjusted target(AT)组75例,目标浓度320-630 pmol/8×10^8 RBC。
  • 随访最长52周或直至停用硫嘌呤治疗。
  • 数据来自Rijnstate Hospital当地医院电子健康软件。

主要发现

  • 52周时151例中100例(66%)停用硫嘌呤治疗。
  • 48例停药为毒性所致(占停药者的48%)。
  • AT组未见疗效丧失。

关键数值与推荐

  • FT组目标6-TGN浓度600-1200 pmol/8×10^8 RBC。
  • AT组目标6-TGN浓度320-630 pmol/8×10^8 RBC。

临床怎么用

  • 在炎症性肠病硫嘌呤治疗中,可考虑采用降低后的6-TGN目标范围(320-630 pmol/8×10^8 RBC)以可能减少毒性停药。
  • 调整目标范围时需监测疗效,因本研究未发现疗效丧失但证据有限。

局限性

  • 回顾性研究设计。
  • 单中心数据,样本量151例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The effect of the Dutch nationwide adjustment of reducing 6-thioguanine nucleotide (6-TGN) target values (from 600-1200 to 320-630 pmol/8 × 108 red blood cells [RBC]) on toxicity and clinical outcome of thiopurine treatment in patients with inflammatory bowel disease has not yet been established. Therefore, the authors determined the incidence of toxicity-induced discontinuations and efficacy at both target concentrations. METHODS: This retrospective study was performed in inflammatory bowel disease patients treated with azathioprine or mercaptopurine. Two groups were defined: the former target (FT) group with target concentrations of 600-1200 pmol/8 × 108 RBC and the adjusted target (AT) group with target concentrations of 320-630 pmol/8 × 108 RBC. Patients were followed for maximum 52 weeks or until discontinuation of thiopurine therapy. Data were collected from the local hospital electronic health software of Rijnstate Hospital. RESULTS: In total, 151 patients were included, 76 in the FT group and 75 in the AT group. At week 52, 100 out of 151 patients (66%) of the total population discontinued thiopurine therapy. Forty-eight of the discontinuations were due toxicity (48%). The incidence of toxicity induced discontinuations was 35% in the AT group vs. 47% in the FT group (P = .25). No loss of efficacy was seen in the AT group. CONCLUSION: After reduction of the target range, there was a trend towards fewer toxicity-induced discontinuations, albeit not statistically significant. In addition, this study did not find any indication that the reduction of the target range diminished efficacy.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Boekema M, Horjus-Talabur Horje CS, Roosenboom B, et al. Therapeutic drug monitoring of thiopurines: Effect of reduced 6-thioguanine nucleotide target levels in inflammatory bowel disease patients. Br J Clin Pharmacol. 2022. PMID: 35293629. doi:10.1111/bcp.15315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。